Literature DB >> 23528693

Towards a functional proteomics approach to the comprehension of idiopathic pulmonary fibrosis, sarcoidosis, systemic sclerosis and pulmonary Langerhans cell histiocytosis.

C Landi1, E Bargagli, L Bianchi, A Gagliardi, A Carleo, D Bennett, M G Perari, A Armini, A Prasse, P Rottoli, L Bini.   

Abstract

Bronchoalveolar lavage fluid of patients with four interstitial lung diseases (sarcoidosis, idiopathic pulmonary fibrosis, pulmonary Langerhans cell histiocytosis, fibrosis associated to systemic sclerosis) and smoker and non smoker control subjects were compared in a proteomic study. Principal component analysis was used to statistically verify the association between differentially expressed proteins and the conditions analyzed. Pathway and functional analysis by MetaCore and DAVID software revealed possible regulatory factors involved in specific "process networks" like regulation of stress and inflammatory responses. Immune response by alternative complement pathways, protein folding, Slit-Robo signaling and blood coagulation were "pathway maps" possibly associated with interstitial lung diseases pathogenesis. Four interesting proteins plastin 2, annexin A3, 14-3-3ε and S10A6 (calcyclin) were validated by Western blot analysis. In conclusion, we identified proteins that could be directly or indirectly linked to the pathophysiology of the different interstitial lung diseases. Multivariate analysis allowed us to classify samples in groups corresponding to the different conditions analyzed and based on their differential protein expression profiles. Finally, functional and pathway analysis defined the potential function and relations among identified proteins, including low abundance molecules present in the MetaCore database. BIOLOGICAL SIGNIFICANCE: This is the first study where different interstitial lung diseases such as sarcoidosis, idiopathic pulmonary fibrosis, pulmonary Langerhans cell histiocytosis, fibrosis associated to systemic sclerosis and smoker and non smoker control subjects were compared in a proteomic study to highlight their common pathways. We decided to report not only principal component analysis, used to statistically verify the association between differentially expressed proteins and the conditions analyzed, but also functional analysis general results, considering all differential proteins potentially involved in these conditions, to speculate about possible common pathogenetic pathways involved in fibrotic lung damage.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23528693     DOI: 10.1016/j.jprot.2013.03.006

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  15 in total

1.  A proteomics approach to identifying key protein targets involved in VEGF inhibitor mediated attenuation of bleomycin-induced pulmonary fibrosis.

Authors:  Yogesh M Kulkarni; Sucharita Dutta; Anand Krishnan V Iyer; Rajkumar Venkatadri; Vivek Kaushik; Vani Ramesh; Clayton A Wright; Oliver John Semmes; Juan S Yakisich; Neelam Azad
Journal:  Proteomics       Date:  2015-11-24       Impact factor: 3.984

2.  Lung Cancer in Patients with Severe Idiopathic Pulmonary Fibrosis: Critical Aspects.

Authors:  Elena Bargagli; Viola Bonti; Katia Ferrari; Elisabetta Rosi; Alessandra Bindi; Maurizio Bartolucci; Moroni Chiara; Luca Voltolini
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

3.  A novel seven-gene risk profile in BALF to identify high-risk patients with idiopathic pulmonary fibrosis.

Authors:  Ziliang Hou; Dan Peng; Jingjing Yang; Shuai Zhang; Jinxiang Wang
Journal:  J Thorac Dis       Date:  2022-05       Impact factor: 3.005

Review 4.  Integrating omics technologies to study pulmonary physiology and pathology at the systems level.

Authors:  Ravi Ramesh Pathak; Vrushank Davé
Journal:  Cell Physiol Biochem       Date:  2014-04-28

Review 5.  Proteomics: Clinical and research applications in respiratory diseases.

Authors:  Katy C Norman; Bethany B Moore; Kelly B Arnold; David N O'Dwyer
Journal:  Respirology       Date:  2018-08-13       Impact factor: 6.424

6.  New Strategies and Challenges in Lung Proteomics and Metabolomics. An Official American Thoracic Society Workshop Report.

Authors:  Russell P Bowler; Chris H Wendt; Michael B Fessler; Matthew W Foster; Rachel S Kelly; Jessica Lasky-Su; Angela J Rogers; Kathleen A Stringer; Brent W Winston
Journal:  Ann Am Thorac Soc       Date:  2017-12

7.  Systemic sclerosis biomarkers detection in the secretome of TGFβ1-activated primary human lung fibroblasts.

Authors:  Ryan T Kendall; Ludivine Renaud; John E Baatz; Maya Malaab; Xinh-Xinh Nguyen; Carol A Feghali-Bostwick
Journal:  J Proteomics       Date:  2021-04-27       Impact factor: 3.855

Review 8.  Molecular biomarkers in interstitial lung diseases.

Authors:  Angelo De Lauretis; Elisabetta A Renzoni
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

9.  Comparative Proteomics Study of Streptozotocin-induced Diabetic Nephropathy in Rats Kidneys Transfected with Adenovirus-mediated Fibromodulin Gene.

Authors:  Akram Maleki; Ali Ramazani; Maryam Foroutan; Alireza Biglari; Parisa Ranjzad; Ali Awsat Mellati
Journal:  Avicenna J Med Biotechnol       Date:  2014-04

10.  Proteomic changes of alveolar lining fluid in illnesses associated with exposure to inhaled non-infectious microbial particles.

Authors:  Laura Teirilä; Kirsi Karvala; Niina Ahonen; Henrik Riska; Anne Pietinalho; Päivi Tuominen; Päivi Piirilä; Anne Puustinen; Henrik Wolff
Journal:  PLoS One       Date:  2014-07-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.